89bio, Inc.

NasdaqGM ETNB

89bio, Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2024: USD -280.54 M

89bio, Inc. Free Cash Flow is USD -280.54 M for the Trailing 12 Months (TTM) ending September 30, 2024, a -129.97% change year over year. Free cash flow is the amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.

89bio, Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -121.99 M, a -48.29% change year over year.
89bio, Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -82.27 M, a -31.40% change year over year.
89bio, Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -62.61 M, a -43.65% change year over year.
89bio, Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2020 was USD -43.58 M, a -146.92% change year over year.

Key data

Date	Free Cash Flow	Operating Cash Flow	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities

NasdaqGM: ETNB

89bio, Inc.

CEO	Mr. Rohan Palekar
IPO Date	Nov. 11, 2019
Location	United States
Headquarters	142 Sansome Street
Employees	70
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.

Key trends

Past 5 years